Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Yijun Jia

Clinical Features of Bim Deletion Polymorphism and Its Relation With Crizotinib Primary Resistance in Chinese Patients With ALK /ROS1 Fusion-Positive Non-Small Cell Lung Cancer

Cancer

Cancer Research

Oncology

2017

English

Related publications

Clinicopathological Features and Clinical Efficacy of Crizotinib in Chinese Patients With ROS1‑positive Non‑small Cell Lung Cancer

English

Prevalence of ROS1 Fusion in Chinese Patients With Non-Small Cell Lung Cancer

English

Differential Crizotinib Response Duration Among ALK Fusion Variants in ALK-Positive Non–Small-Cell Lung Cancer

Journal of Clinical Oncology

English

P1.01-113 Analysis of Clinicopathological Features and Clinical Efficacy of Crizotinib in ROS1 Positive Non-Small Cell Lung Cancer

Journal of Thoracic Oncology

English

P3.15-31 Better Clinical Outcomes and Resistance Mechanisms of Crizotinib in ALK-Positive Non-Small Cell Lung Cancer

Journal of Thoracic Oncology

English

Efficacy and Safety of Crizotinib Among Chinese EML4-ALK-Positive, Advanced-Stage Non-Small Cell Lung Cancer Patients

PLoS ONE

Multidisciplinary

2014

English

Chinese Perspectives on Clinical Efficacy and Safety of Alectinib in Patients With ALK-positive Advanced Non-Small Cell Lung Cancer

OncoTargets and Therapy

Oncology

Pharmacology

2019

English

Crizotinib Improves Osteoarthritis Symptoms in a ROS1-Fusion Advanced Non–Small Cell Lung Cancer Patient

Journal of Thoracic Oncology

English

174P: Comparison of Cardiovascular Effects of Crizotinib and Chemotherapy in Patients (Pts) With ALK-positive (+) Advanced Non-Small Cell Lung Cancer (NSCLC)

Journal of Thoracic Oncology

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Yijun Jia

Clinical Features of Bim Deletion Polymorphism and Its Relation With Crizotinib Primary Resistance in Chinese Patients With ALK /ROS1 Fusion-Positive Non-Small Cell Lung Cancer

Related publications

Clinicopathological Features and Clinical Efficacy of Crizotinib in Chinese Patients With ROS1‑positive Non‑small Cell Lung Cancer

Prevalence of ROS1 Fusion in Chinese Patients With Non-Small Cell Lung Cancer

Differential Crizotinib Response Duration Among ALK Fusion Variants in ALK-Positive Non–Small-Cell Lung Cancer

P1.01-113 Analysis of Clinicopathological Features and Clinical Efficacy of Crizotinib in ROS1 Positive Non-Small Cell Lung Cancer

P3.15-31 Better Clinical Outcomes and Resistance Mechanisms of Crizotinib in ALK-Positive Non-Small Cell Lung Cancer

Efficacy and Safety of Crizotinib Among Chinese EML4-ALK-Positive, Advanced-Stage Non-Small Cell Lung Cancer Patients

Chinese Perspectives on Clinical Efficacy and Safety of Alectinib in Patients With ALK-positive Advanced Non-Small Cell Lung Cancer

Crizotinib Improves Osteoarthritis Symptoms in a ROS1-Fusion Advanced Non–Small Cell Lung Cancer Patient

174P: Comparison of Cardiovascular Effects of Crizotinib and Chemotherapy in Patients (Pts) With ALK-positive (+) Advanced Non-Small Cell Lung Cancer (NSCLC)